Physician profile
Bailey S Moore
NPI 1790441533
$3,017.70
in general payments reported to CMS, 2019-2025
18 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.81 · 2022: $101 · 2023: $55.60 · 2024: $391 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777 · Consulting Fee: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.83 |
| Consulting Fee | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,465.21 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $375.10 | 2021-2025 | |
| Lilly USA, LLC | $237.51 | 2024-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $212.79 | 2025 | Nemluvio |
| Genzyme Corporation | $182.67 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $76.63 | 2024-2025 | Zoryve |
| Mallinckrodt Hospital Products INC. | $71.96 | 2024-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $62.87 | 2024 | Dupixent |
| Ucb, INC. | $45.39 | 2025 | Bimzelx |
| Incyte Corporation | $45.06 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $39.61 | 2022-2025 | |
| Kerecis Limited | $36.90 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Amgen INC. | $34.89 | 2024 | Otezla |
| Dermavant Sciences, INC. | $34.75 | 2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $31.75 | 2024-2025 | Nuzyra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $26.78 | 2025 | Collagenase Santyl |
| Janssen Scientific Affairs, LLC | $24.51 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $13.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.